

a nemůžeme očekávat zázrak v podobě vynalezení léku s excesivním účinkem na sílu a trvání léčebné odpovědi. Zlepšení para-

metrů OS a PFS, kterých bylo dosaženo ve studii ADRIATIC, představuje výrazný příznivý „skok“ v léčbě, proto lze souhlasit s názorem

autorů, kteří označují přidání durvalumabu po absolvování chemoradioterapie za revoluční léčbu LD-SCLC.

LITERATURA

1. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. doi: 10.1038/s41572-020-00235-0.
2. Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025;333(21):1906-1917. doi:10.1001/jama.2025.0560.
3. Jett JR, Schild SE, Kesler KA, et al. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinica practice guidelines. Chest. 2013;143(5 Suppl):e211S-e250S. doi: 10.1378/chest.12-2355. PMID: 23649440.
4. Kalemkerian GP, Gadgil SM. Modern staging of small cell lung cancer. J Natl Compr Canc Netw. 2013;11(1):99-104. doi: 10.6004/jnccn.2013.0012. PMID: 23307985.
5. Toh TS, Lok BH. Limited-Stage Small-Cell Lung Cancer: Current Progress and the Next Frontier. Radiation. 2021;1(4):317-333. <https://doi.org/10.3390/radiation1040026>.
6. Uprety D, Seaton R, Niroula A, et al. Trends in the Incidence and Survival Outcomes in Patients With Small Cell Lung Cancer in the United States: An Analysis of the SEER Database. Cancer Med. 2025;14(3):e70608. doi: 10.1002/cam4.70608. PMID: 39908169; PMCID: PMC11797299.
7. Krejčí D, Mužík J, Dušek L. Novotvary 2019–2021 ČR. Cancer incidence 2019–2021 in the Czech Republic. [cited 20. 8. 2025] Available from: <https://www.uzis.cz/res/f/008447/novotvary2019-2021.pdf>.
8. Mathieu L, Shah S, Pai-Scherf L, et al. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer. Oncologist. 2021;26(5):433-438. doi: 10.1002/onco.13752.

9. Lim JU, Ryu WK, Park N, et al. Current and future perspectives in extensive-stage small-cell lung cancer. Ther Adv Med Oncol. 2025;17:17588359251326705. doi: 10.1177/17588359251326705.
10. Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2017;12(7):1109-1121. doi: 10.1016/j.jtho.2017.04.011. Epub 2017 Apr 28. PMID: 28461257.
11. Lad T, Piantadosi S, Thomas P, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest. 1994;106(6 Suppl):320S-323S. doi: 10.1378/chest.106.6_supplement.320S. PMID: 7988254.
12. Yang CJ, Chan DY, Shah SA, et al. Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer. Ann Surg. 2018;268(6):1105-1112. doi: 10.1097/SLA.0000000000002287. PMID: 28475559.
13. Noronha V, Sekhar A, Patil VM, et al. Systemic therapy for limited stage small cell lung carcinoma. J Thorac Dis. 2020;12(10):6275-6290. doi: 10.21037/jtd-2019-sclc-11.
14. Veslemes M, Polyzos A, Latsi P, et al. Optimal duration of chemotherapy in small cell lung cancer: a randomized study of 4 versus 6 cycles of cisplatin-etoposide. J Chemother 1998;10:136-140. doi: 10.1179/joc.1998.10.2.136.
15. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. N Engl J Med. 1992;327(23):1618-1624. doi: 10.1056/NEJM199212033272302. PMID: 1331787.

16. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. J Clin Oncol. 1992;10(6):890-895. doi: 10.1200/JCO.1992.10.6.890. PMID: 1316951.
17. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20(14):3054-3060. doi: 10.1200/JCO.2002.12.071. PMID: 12118018.
18. Wu Q, Xiong Y, Zhang S, et al. A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials. Front Oncol. 2020;9:1460. doi: 10.3389/fonc.2019.01460. PMID: 31970086; PMCID: PMC6960125.
19. Spigel DR, Cheng Y, Cho BC, et al. ADRIATIC: durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer (LS-SCLC). ASCO 2024, 31.5–4.6, Chicago, USA.
20. Senan S, et al. (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial. ESMO Congress 2024, September 13–17, Barcelona, Spain, LBA81.
21. Senan, et al. Patterns of disease progression with durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Results from ADRIATIC. ELCC 2025, March 26–29, Paris, France.



FACEBOOK

<https://www.facebook.com/SolenMedicalEducation/>

@SolenMedicalEducation



INSTAGRAM

https://www.instagram.com/solen_cz/

@solen_cz



LINKEDIN

<https://www.linkedin.com/company/solen-medical-education/>

#solenmedicaleducation

» ODEMČENÉ **AKTUÁLNÍ ČLÁNKY**

» **PŘEHLED** O VZDĚLÁVACÍCH AKCÍCH

» UPOZORNĚNÍ NA **ZVÝHODNĚNÉ CENY**

» **SOUTĚŽE** O VSTUPENKY NA KONGRESY

» INFORMACE O **ON-LINE** KURZECH

» NOVINKY V **E-SHOPU**

... a mnoho dalšího

... **nenechte si ujít aktuální informace**
o možnostech medicínského vzdělávání